Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Merkel cell carcinoma expresses vasculogenic mimicry: demonstration in patients and experimental manipulation in xenografts.

Lezcano C, Kleffel S, Lee N, Larson AR, Zhan Q, DoRosario A, Wang LC, Schatton T, Murphy GF.

Lab Invest. 2014 Oct;94(10):1092-102. doi: 10.1038/labinvest.2014.99. Epub 2014 Aug 11.

2.

ABCB5-Targeted Chemoresistance Reversal Inhibits Merkel Cell Carcinoma Growth.

Kleffel S, Lee N, Lezcano C, Wilson BJ, Sobolewski K, Saab KR, Mueller H, Zhan Q, Posch C, Elco CP, DoRosario A, Garcia SS, Thakuria M, Wang YE, Wang LC, Murphy GF, Frank MH, Schatton T.

J Invest Dermatol. 2016 Apr;136(4):838-46. doi: 10.1016/j.jid.2015.12.038. Epub 2016 Jan 29.

3.

Growth and characterization of a cell line from a human primary neuroendocrine carcinoma of the skin (Merkel cell carcinoma) in culture and as xenograft.

Krasagakis K, Almond-Roesler B, Geilen C, Fimmel S, Krengel S, Chatzaki E, Gravanis A, Orfanos CE.

J Cell Physiol. 2001 Jun;187(3):386-91.

PMID:
11319762
4.

The embryonic morphogen, Nodal, is associated with channel-like structures in human malignant melanoma xenografts.

McAllister JC, Zhan Q, Weishaupt C, Hsu MY, Murphy GF.

J Cutan Pathol. 2010 Apr;37 Suppl 1:19-25. doi: 10.1111/j.1600-0560.2010.01503.x.

5.

Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts.

Orecchia P, Conte R, Balza E, Pietra G, Mingari MC, Carnemolla B.

Oncotarget. 2015 Nov 10;6(35):37426-42. doi: 10.18632/oncotarget.6055.

6.

Induction of durable responses by oral etoposide monochemotherapy in patients with metastatic Merkel cell carcinoma.

Schlaak M, Podewski T, Von Bartenwerffer W, Kreuzberg N, Bangard C, Mauch C, Kurschat P.

Eur J Dermatol. 2012 Mar-Apr;22(2):187-91. doi: 10.1684/ejd.2011.1634.

PMID:
22240092
7.

Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth.

Kannan A, Lin Z, Shao Q, Zhao S, Fang B, Moreno MA, Vural E, Stack BC Jr, Suen JY, Kannan K, Gao L.

Oncotarget. 2016 Feb 9;7(6):6576-92. doi: 10.18632/oncotarget.5878.

8.

Merkel cell carcinoma: identification of prognostic factors unique to tumors located in the head and neck based on analysis of SEER data.

Smith VA, Camp ER, Lentsch EJ.

Laryngoscope. 2012 Jun;122(6):1283-90. doi: 10.1002/lary.23222. Epub 2012 Apr 20.

PMID:
22522673
9.

Tumor location is an independent prognostic factor in head and neck Merkel cell carcinoma.

Smith VA, MaDan OP, Lentsch EJ.

Otolaryngol Head Neck Surg. 2012 Mar;146(3):403-8. doi: 10.1177/0194599811431789. Epub 2011 Dec 13.

PMID:
22166964
10.

Advanced Merkel cell cancer and the elderly.

Bird BR, Myers D, Ryan SM, Wyse G, O'Sullivan ST, Breathnach OS.

Ir J Med Sci. 2005 Jan-Mar;174(1):58-60.

PMID:
15868892
11.

Synchronous onset of multiple cutaneous neuroendocrine (Merkel cell) carcinomas localized to the scalp.

Satter EK, Derienzo DP.

J Cutan Pathol. 2008 Jul;35(7):685-91. doi: 10.1111/j.1600-0560.2007.00874.x. Epub 2008 Mar 10.

PMID:
18331571
12.

Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses.

Dowlatshahi M, Huang V, Gehad AE, Jiang Y, Calarese A, Teague JE, Dorosario AA, Cheng J, Nghiem P, Schanbacher CF, Thakuria M, Schmults CD, Wang LC, Clark RA.

J Invest Dermatol. 2013 Jul;133(7):1879-89. doi: 10.1038/jid.2013.75. Epub 2013 Feb 18.

13.

Vascular changes in merkel cell carcinoma based on a histopathological study of 92 cases.

Vazmitel M, Michal M, Shelekhova KV, Sima R, Mukensnabl P, Kazakov DV.

Am J Dermatopathol. 2008 Apr;30(2):106-11. doi: 10.1097/DAD.0b013e318162eaa2.

PMID:
18360111
14.

Merkel cell carcinoma: report of 10 cases and review of the literature.

Akhtar S, Oza KK, Wright J.

J Am Acad Dermatol. 2000 Nov;43(5 Pt 1):755-67. Review.

PMID:
11050578
15.

Merkel cell carcinoma of the eyelid: management and prognosis.

Herbert HM, Sun MT, Selva D, Fernando B, Saleh GM, Beaconsfield M, Collin R, Uddin J, Meligonis G, Leatherbarrow B, Ataullah S, Irion L, McLean CJ, Huilgol SC, Davis G, Sullivan TJ.

JAMA Ophthalmol. 2014 Feb;132(2):197-204. doi: 10.1001/jamaophthalmol.2013.6077.

PMID:
24287584
16.

High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study--TROG 96:07.

Poulsen M, Rischin D, Walpole E, Harvey J, Mackintosh J, Ainslie J, Hamilton C, Keller J, Tripcony L; Trans-Tasman Radiation Oncology Group.

J Clin Oncol. 2003 Dec 1;21(23):4371-6.

PMID:
14645427
17.

Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens.

Houben R, Shuda M, Weinkam R, Schrama D, Feng H, Chang Y, Moore PS, Becker JC.

J Virol. 2010 Jul;84(14):7064-72. doi: 10.1128/JVI.02400-09. Epub 2010 May 5.

18.

Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system.

Lemos BD, Storer BE, Iyer JG, Phillips JL, Bichakjian CK, Fang LC, Johnson TM, Liegeois-Kwon NJ, Otley CC, Paulson KG, Ross MI, Yu SS, Zeitouni NC, Byrd DR, Sondak VK, Gershenwald JE, Sober AJ, Nghiem P.

J Am Acad Dermatol. 2010 Nov;63(5):751-61. doi: 10.1016/j.jaad.2010.02.056. Epub 2010 Jun 19.

19.

HIF-1α induces VE-cadherin expression and modulates vasculogenic mimicry in esophageal carcinoma cells.

Tang NN, Zhu H, Zhang HJ, Zhang WF, Jin HL, Wang L, Wang P, He GJ, Hao B, Shi RH.

World J Gastroenterol. 2014 Dec 21;20(47):17894-904. doi: 10.3748/wjg.v20.i47.17894.

20.

[Merkel cell carcinoma: follow-up of 10 patients. Current diagnosis and therapy].

Hauschild A, Rademacher D, Röwert J, Christophers E.

Langenbecks Arch Chir. 1997;382(4):185-91. German.

PMID:
9445964

Supplemental Content

Support Center